Plasmapheresis ( DrugBank: - )

3 diseases

11. 重症筋無力症

臨床試験数 : 315 / 薬物数 : 232 - (DrugBank : 77) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-002817-37-IT (EUCTR)	29/07/2008	30/06/2008	A PHASE II, PLACEBO CONTROLLED, DOSE FINDING PILOT STUDY OF PIXANTRONE EFFICACY ADMINISTERED INTRAVENOUSLY IN PATIENTS AFFECTED WITH MYASTHENIA GRAVIS - ND	A PHASE II, PLACEBO CONTROLLED, DOSE FINDING PILOT STUDY OF PIXANTRONE EFFICACY ADMINISTERED INTRAVENOUSLY IN PATIENTS AFFECTED WITH MYASTHENIA GRAVIS - ND	Patients affected with MG showing clinically meaningful improvement after therapeutic plasmapheresis. MedDRA version: 9.1;Level: LLT;Classification code 10028417;Term: Myasthenia gravis	Product Name: PIXANTRONE Product Code: BBR 2778 INN or Proposed INN: pixantrone	ISTITUTO NEUROLOGICO CARLO BESTA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Italy
2	NCT00515450 (ClinicalTrials.gov)	July 2007	10/8/2007	Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis	A Randomized, Controlled Clinical Study of GB-0998 for Treatment of Generalized Myasthenia Gravis	Generalized Myasthenia Gravis	Biological: GB-0998 (Intravenous immunoglobulin);Procedure: Plasmapheresis	Benesis Corporation	NULL	Completed	16 Years	N/A	Both	46	Phase 3	Japan

臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00230035 (ClinicalTrials.gov)	September 2005	28/9/2005	Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)	A Randomized, Open Label, Phase II Multicenter Study of Non-Myeloablative Autologous Transplantation With Auto-CD34+HPC Versus Currently Available Immunosuppressive/Immunomodulatory Therapy for Treatment of Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Procedure: Leukapheresis;Procedure: Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT);Procedure: Autologous CD34+HPC transplantation (HSCT);Procedure: Plasmapheresis;Drug: Rabbit anti-thymocyte globulin;Drug: Methylprednisolone;Drug: Growth colony stimulating factor (G-CSF);Drug: Corticosteroids;Drug: Mycophenolate mofetil;Drug: Azathioprine;Drug: Intravenous immunoglobulin;Drug: Methotrexate;Drug: Rituximab;Drug: Leflunomide	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Withdrawn	18 Years	60 Years	Both	0	Phase 2	United States

臨床試験数 : 285 / 薬物数 : 285 - (DrugBank : 108) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 191

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03763643 (ClinicalTrials.gov)	July 1, 2019	7/8/2018	PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant	PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant	Focal Segmental Glomerulosclerosis	Drug: Rituximab;Procedure: Plasmapheresis	University of Minnesota	United States Department of Defense	Recruiting	1 Year	65 Years	All	160	Phase 3	United States